Krasney Karen 4
4 · CAPRICOR THERAPEUTICS, INC. · Filed Apr 1, 2026
Research Summary
AI-generated summary of this filing
Capricor (CAPR) EVP Karen Krasney Exercises Options, Sells 25,000 Shares
What Happened
Karen Krasney, EVP and General Counsel of Capricor Therapeutics (CAPR), exercised stock options to acquire a total of 25,000 shares on March 31, 2026 (three option tranches: 693 @ $1.39, 21,488 @ $3.74, and 2,819 @ $3.18). The same day she sold 25,000 shares in the open market at a weighted average price of $30.12, generating proceeds of $752,935. The filing shows the related option instruments were terminated (reported as dispositions at $0.00) when exercised.
Key Details
- Transaction date: March 31, 2026; Form 4 filed April 1, 2026 (appears timely).
- Options exercised: 25,000 shares total for aggregate exercise cost ≈ $90,292 (693×$1.39 = $963; 21,488×$3.74 = $80,365; 2,819×$3.18 = $8,964).
- Open-market sale: 25,000 shares sold at a weighted average price $30.12 for total proceeds $752,935; sale prices ranged $30.00–$30.31. (Footnote: sale pursuant to a 10b5-1 trading plan adopted Dec 2025.)
- Net effect: The filing shows 25,000 shares acquired and 25,000 shares sold same day—no net increase in shares beneficially owned per these transactions. The Form does not list an updated total shareholding in the provided data.
- Option details/vesting: Options referenced were granted Jan 2, 2018 (adjusted for a 2019 reverse split and a 2020 reprice); vesting schedules noted in the filing (monthly vesting in the referenced tranches).
Context
These transactions reflect an exercise of previously granted options followed by an immediate sale of the resulting shares under a pre-established 10b5-1 plan. That pattern is commonly used to monetize vested option gains and does not, by itself, indicate a change in the insider’s long-term view of the company. The derivative entries reported as disposed at $0.00 reflect the termination/conversion of the option instruments upon exercise.
Insider Transaction Report
- Exercise/Conversion
Common Stock
2026-03-31$1.39/sh+693$963→ 31,240 total - Exercise/Conversion
Common Stock
2026-03-31$3.74/sh+21,488$80,365→ 52,728 total - Exercise/Conversion
Common Stock
2026-03-31$3.18/sh+2,819$8,964→ 55,547 total - Sale
Common Stock
[F1][F2]2026-03-31$30.12/sh−25,000$752,935→ 30,547 total - Exercise/Conversion
Stock Option (Right to Buy)
[F3][F4]2026-03-31−693→ 2,807 totalExercise: $1.39Exp: 2028-01-02→ Common Stock (693 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
[F5]2026-03-31−21,488→ 74,205 totalExercise: $3.74Exp: 2031-01-04→ Common Stock (21,488 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
[F6]2026-03-31−2,819→ 81,261 totalExercise: $3.18Exp: 2032-01-03→ Common Stock (2,819 underlying)
Footnotes (6)
- [F1]Shares were sold pursuant to a 10b5-1 trading plan adopted in December 2025 by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
- [F2]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.31, inclusive.
- [F3]This option was granted on January 2, 2018 and was previously reported as covering 35,000 shares at an exercise price of $1.57 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice of $1.39 per share that occurred on February 12, 2020.
- [F4]Shares vested 1/48th on the first day of each month commencing February 1, 2018.
- [F5]Shares vested 1/48th on the first day of each month commencing February 1, 2021.
- [F6]Shares vested 1/48th on the first day of each month commencing February 1, 2022.